RxDoctor Payments Data

Phillip Pierorazio, MD

Urology · Philadelphia, PANPI 1528182003

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (54.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Johnson & Johnson at 40.7% of the total. Reporting peaked in 2022 at $9,667 and has fallen 77.3% since, to $2,195 in 2025. Among urology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$38,710in general payments, 2019–2025

Across 109 payments — averaging $355.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$16K
  • Urogen Pharma, Inc.$11K
  • Intuitive Surgical$5K
  • Surgical Specialties Corporation (US), Inc. (dba Corza Medical)$2K
  • Merck$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • plus $3K from 16 others
$81,903in research payments, 2019–2025

Across 26 payments — averaging $3150.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Urogen Pharma, Inc.$45K
  • Ferring Pharmaceuticals AS$37K

What the payments were for

  • Consulting fees$21,17555%
  • Speaking & faculty fees$7,90020%
  • Travel & lodging$3,4919%
  • Food & beverage$6,14416%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,710 in reported general payments places this provider in the 90th percentile of 596 urology providers in Pennsylvania.

See all urology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$125,025
Medicare patients
302
Services billed
488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Finasteride17$51

Paid to pharmacies, not to this prescriber.

Other urology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →